AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Onconetix Subsidiary Signs Licensing Agreement with Immunovia for $700,000 and Royalties.
ByAinvest
Monday, Sep 22, 2025 8:03 am ET1min read
• Onconetix subsidiary Proteomedix signs licensing deal with Immunovia • Immunovia gets master cells, IP license, and reagent manufacturing rights • Proteomedix receives $700,000 in 2025 and 2026, plus 3% royalty on PancreaSure sales • Agreement enhances Proteomedix's biomarker testing capabilities for pancreatic cancer.
Proteomedix, a subsidiary of Onconetix, has signed a licensing agreement with Immunovia, further bolstering its biomarker testing capabilities for pancreatic cancer. Under the terms of the deal, Immunovia will receive a master cell line, intellectual property (IP) license, and rights to manufacture reagents. In exchange, Proteomedix will receive a $700,000 upfront payment for 2025 and 2026, as well as a 3% royalty on sales of Immunovia's PancreaSure test [1].The agreement strengthens Proteomedix's position in the biomarker testing market, particularly for pancreatic cancer. Immunovia's PancreaSure test, which is based on Proteomedix's proprietary technology, has shown promising results in clinical trials. The deal is expected to enhance Proteomedix's ability to provide accurate and reliable biomarker testing services, which are crucial for early detection and treatment of pancreatic cancer.
The signing of this deal follows a series of strategic partnerships and licensing agreements in the biotechnology sector. For instance, Monte Rosa Therapeutics recently entered into a collaboration with Novartis to develop novel molecular glue degraders (MGD) for immune-mediated diseases [2]. Similarly, Alligator Bioscience announced final results from its OPTIMIZE-1 trial, demonstrating the potential of its lead asset, mitazalimab, in combination with chemotherapy for metastatic pancreatic cancer [2].
These developments underscore the growing importance of strategic partnerships and licensing deals in advancing therapeutic and diagnostic technologies. As the market for biomarker testing continues to grow, companies like Proteomedix are positioning themselves to capitalize on this opportunity by leveraging strong partnerships and proprietary technologies.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet